In 50 postmenopausal women at high fracture risk, 3 months of romosozumab then denosumab was non-inferior to 12 months of romosozumab for 12-month total hip BMD change (mean 5.7% vs 6.0%); adverse events were balanced.
RCTn = 50
Leder et al. 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial